[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340171-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340171-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","rna-m6a-modification-in-ferroptosis-implications-for-advancing-tumor-immunotherapy-review","RNA m6A modification in ferroptosis: implications for advancing tumor immunotherapy - Review","","The review addresses the need for more effective oncology treatments in the face of persistent cancer mortality. It frames immunotherapy as a promising systemic approach, while emphasizing challenges of low response rates and immune resistance. Ferroptosis is presented as a reprogrammed, iron-dependent, nonapoptotic cell death linked to the tumor immune environment. The article explains how dysregulated RNA m6A modification can alter ferroptosis susceptibility and immune checkpoint expression. It concludes that clarifying m6A-driven ferroptosis regulation may reveal targets to improve immune-resistant tumor immunotherapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/rna-m6a-modification-in-ferroptosis-implications-for-advancing-tumor-immunotherapy-review/340171/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/rna-m6a-modification-in-ferroptosis-implications-for-advancing-tumor-immunotherapy-review/340171.png","ImageObject",300,407,{"name":42,"@type":43},"Rowan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why does the review focus on improving tumor immunotherapy effectiveness?","Question",{"text":63,"@type":64},"Because immunotherapy is promising but still faces limited immune response rates and immune resistance, which hinder consistent therapeutic success.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is ferroptosis and how is it connected to the tumor immune environment?",{"text":68,"@type":64},"Ferroptosis is a reprogrammed, iron-dependent nonapoptotic cell death tightly correlated with the tumor immune environment and linked to cancer progression.",{"name":70,"@type":61,"acceptedAnswer":71},"How does RNA m6A modification influence ferroptosis and immune checkpoints?",{"text":72,"@type":64},"Aberrant m6A modification affects cell susceptibility to ferroptosis and is involved in the expression of immune checkpoints, impacting how tumors respond to immunotherapy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340171,1790240575,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Shi et al. Molecular Cancer (2024) 23:213 [https://doi.org/10.1186/s12943-024-02132-6](https://doi.org/10.1186/s12943-024-02132-6)  \nMolecular Cancer  \n REVIEW Open Access  \nRNA m6A modification in ferroptosis: implications for advancing tumor immunotherapy  \nJun-xiao Shi1†, Zhi-chao Zhang1†, Hao-zan Yin2†, Xian-jie Piao 1†, Cheng-hu Liu 1, Qian-jia Liu 1, Jia-cheng Zhang1, Wen-xuan Zhou 1, Fu-chen Liu 1, Fu Yang2,3,4*, Yue-fan Wang1* and Hui Liu 1*  \nAbstract  \nThe pursuit of innovative therapeutic strategies in oncology remains imperative, given the persistent global impact of cancer as a leading cause of mortality. Immunotherapy is regarded as one of the most promising techniques for systemic cancer therapies among the several therapeutic options available. Nevertheless, limited immune response rates and immune resistance urge us on an augmentation for therapeutic efficacy rather than sticking to conventional approaches. Ferroptosis, a novel reprogrammed cell death, is tightly correlated with the tumor immune environment and interferes with cancer progression. Highly mutant or metastasis-prone tumor cells are more susceptible to iron-dependent nonapoptotic cell death. Consequently, ferroptosis-induction therapies hold the promise of overcoming resistance to conventional treatments. The most prevalent post-transcriptional modification, RNA m6A modification, regulates the metabolic processes of targeted RNAs and is involved in numerous physiological and pathological processes. Aberrant m6A modification influences cell susceptibility to ferroptosis, as well as the expression of immune checkpoints. Clarifying the regulation of m6A modification on ferroptosis and its significance in tumor cell response will provide a distinct method for finding potential targets to enhance the effectiveness of immunotherapy. In this review, we comprehensively summarized regulatory characteristics of RNA m6A modification on ferroptosis and discussed the role of RNA m6A-mediated ferroptosis on immunotherapy, aiming to enhance the effectiveness offerroptosis-sensitive immunotherapy as a treatment for immune-resistant malignancies.  \n†Jun-xiao Shi, Zhi-chao Zhang, Hao-zan Yin, and Xian-jie Piao contributed equally to this work.  \n*Correspondence:  \nFu Yang [yangfusq1997@smmu.edu.cn](yangfusq1997@smmu.edu.cn)[ ](yangfusq1997@smmu.edu.cn)[Yue-fan Wang](Yue-fan Wang)[ ](Yue-fan Wang)[wangyuefan2015@163.com](wangyuefan2015@163.com)[ ](wangyuefan2015@163.com)Hui Liu  \n[liuhuigg@hotmail.com](liuhuigg@hotmail.com)  \n1 The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai 200438, China  \n2 The Department of Medical Genetics, Naval Medical University, Shanghai 200433, China  \n3 Key Laboratory of Biosafety Defense, Ministry of Education, Shanghai 200433, China  \n4 Shanghai Key Laboratory of Medical Biodefense, Shanghai 200433, China  \n© The Author(s) 2024, corrected publication 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://cre","cbCaik3IKyKaXiXY","https://ap.wps.com/l/cbCaik3IKyKaXiXY","pdf",4573283,39,"English","# Introduction\n## Immune evasion and the role of immunotherapy\n## Major immunotherapy modalities and limitations","[{\"question\":\"Why does the review focus on improving tumor immunotherapy effectiveness?\",\"answer\":\"Because immunotherapy is promising but still faces limited immune response rates and immune resistance, which hinder consistent therapeutic success.\"},{\"question\":\"What is ferroptosis and how is it connected to the tumor immune environment?\",\"answer\":\"Ferroptosis is a reprogrammed, iron-dependent nonapoptotic cell death tightly correlated with the tumor immune environment and linked to cancer progression.\"},{\"question\":\"How does RNA m6A modification influence ferroptosis and immune checkpoints?\",\"answer\":\"Aberrant m6A modification affects cell susceptibility to ferroptosis and is involved in the expression of immune checkpoints, impacting how tumors respond to immunotherapy.\"}]","RNA m6A modification in ferroptosis: implications for advancing tumor immunotherapy - Review | PDF",1790034648,98,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e49b0ec127a1ef0f39ac3d04df34287.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3169a8e034d72c21348fd8a79a07c7bf.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc8eeac1af7efd5933e97c719fcd9f8d.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc60dd5ca5f6ea360c4104106f4c04f6.webp",980,1301]